A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long‐term follow‐up in newly diagnosed mantle cell lymphoma

Authors:

Abstract
Summary: Mantle cell lymphoma (MCL) is associated with high relapse rates and poor survival when treated with conventional chemotherapy, with or without rituximab. We report the long‐term follow‐up of a phase II clinical trial using a new intensive multiagent chemotherapeutic regimen [cyclophosphamide, teniposide, doxorubicin and prednisone (CTAP) alternating with vincristine and high‐dose methotrexate and cytarabine (VMAC)] in newly diagnosed MCL. Following 4–6 cycles of CTAP/VMAC induction, patients aged ≤65 years proceeded to consolidative autologous haematopoietic stem cell transplantation (auto‐HSCT), while patients ≤55 years who had a HLA‐identical sibling received allogeneic‐HSCT (busulfan/cyclophosphamide conditioning for both). Twenty‐five untreated MCL patients enrolled on the protocol between 1997 and 2002. Among evaluable patients, overall response rate (ORR) was 74% following induction chemotherapy. Seventeen patients received HSCT (autologous‐13/allogeneic‐4). On intent‐to‐treat analysis, ORR for patients who received consolidative HSCT was 100% (complete remission 76%). Therapy was well‐tolerated with 4% treatment‐related mortality (including HSCT). The 5‐year event‐free‐survival (EFS) and overall survival (OS) for all patients was 35% and 50% respectively. Furthermore, at 66‐months median follow‐up, the 5‐year EFS and OS for patients who received consolidative auto‐HSCT was 54% and 75% respectively. Patients who received auto‐HSCT had improved outcomes compared to no auto‐HSCT (EFSP = 0·001; OSP = 0·0002). CTAP/VMAC induction followed by consolidative auto‐HSCT for newly diagnosed MCL is associated with high ORR and durable survival.

This publication has 34 references indexed in Scilit: